Publications by authors named "Hitisha Patel"

Claim this Profile
M
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
Taronish D Dubash, Aditya Bardia, Brian Chirn, Brittany A Reeves, Joseph A LiCausi, Hitisha Patel

Breast Cancer Res Treat· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.
Sunil Pancholi, Nikiana Simigdala, Ricardo Ribas, Eugene Schuster, Mariana Ferreira Leal, Hitisha Patel

NPJ Breast Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Hitisha K Patel, Nianjun Tao, Kyung-Min Lee, Mariela Huerta, Heike Arlt

Breast Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment.
Hitisha K Patel, Teeru Bihani

Pharmacol Ther· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.
Ziyang Yu, Suqin He, Dannie Wang, Hitisha K Patel, Chris P Miller

Clin Cancer Res· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER Breast Cancer Patient-derived Xenograft Models.
Teeru Bihani, Hitisha K Patel, Heike Arlt, Nianjun Tao, Hai Jiang

Clin Cancer Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.
Rui Xiong, Hitisha K Patel, Lauren M Gutgesell, Jiong Zhao, Loruhama Delgado-Rivera

J Med Chem· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer.
Mary Ellen Molloy, Bethany E Perez White, Teshome Gherezghiher, Bradley T Michalsen, Rui Xiong, Hitisha Patel

Mol Cancer Ther· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SERMs attenuate estrogen-induced malignant transformation of human mammary epithelial cells by upregulating detoxification of oxidative metabolites.
L P Madhubhani P Hemachandra, Hitisha Patel, R Esala P Chandrasena, Jaewoo Choi, Sujeewa C Piyankarage

Cancer Prev Res (Phila)· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy.
Hitisha K Patel, Marton I Siklos, Hazem Abdelkarim, Emma L Mendonca, Aditya Vaidya

ChemMedChem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis